Alzamend Neuro
Business Services · Georgia, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3480 Peachtree Rd NE Fl Second Ste 103, ...Phone Number
(844) 722-6333Website
www.alzamend.comRevenue
-Stock Symbol
ALZNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Alzamend Neuro
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company headquartered in Atlanta, Georgia, focused on developing treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and PTSD. Its pipeline includes AL001, an ionic cocrystal therapy combining lithium, salicylate, and L-proline, and ALZN002, a cell-based therapeutic vaccine targeting beta-amyloid in Alzheimer’s disease. Alzamend is also collaborating with Massachusetts General Hospital on Phase II clinical trials evaluating AL001 for brain lithium delivery.Explore more
Alzamend Neuro Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alzamend Neuro your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Alzamend Neuro has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Alzamend Neuro
Alzamend Neuro, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Alzamend Neuro is spiking on competitors!
Click to see if Alzamend Neuro had a recent Job posting/layoffs
Product Launch: Get notified when Alzamend Neuro launches new products
Funding: Get notified immidiatlly once Alzamend Neuro has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Alzamend Neuro recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Alzamend Neuro
Compare insights from companies similar to Alzamend Neuro, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alzamend Neuro is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Alzamend Neuro is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Alzamend Neuro.
Alzamend Neuro financials insights
Gather financial insights about Alzamend Neuro, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Share Placement
$10M
Stock Offering
$12.5M
2022
Private Equity
$4M
Alzamend Neuro Tech Stack
A closer look at the technologies used by Alzamend Neuro
See more technologies
Most Recent Scoops
Event
Milton Ault, Chairman and Founder, has appeared on a podcast called "Success Story with Scott D. Clary" on 07/01/2024. Topics discussed include Entrepreneurship, public markets, legal battles.
Project
Financial Planning
Event
Events
Event
Events
Project
Product Development
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alzamend Neuro
Sign Up For FreeTo access detailed company insights
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company headquartered in Atlanta, Georgia, focused on developing treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and PTSD. Its pipeline includes AL001, an ionic cocrystal therapy combining lithium, salicylate, and L-proline, and ALZN002, a cell-based therape... Read More
